Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Evaluación de seguridad y eficacia a largo plazo de Lunsekimig (SAR443765) en participantes adultos con asma moderada a grave. (AIRPHRODITE)

18 de septiembre de 2026 actualizado por: Sanofi

Un estudio de extensión de etiqueta abierta para evaluar la seguridad y eficacia a largo plazo del Lunsekimig subcutáneo en participantes adultos con asma moderada a grave que participaron en el estudio DRI16762

This is a phase 2, open-label extension study to evaluate the long-term safety and efficacy of lunsekimig in adult participants with asthma who have previously completed the parent studies. After completion of the parent study, eligible participants will be offered the opportunity to participate in the long-term extension (LTE) study with lunsekimig.

The study duration will be up to 148 weeks with a treatment duration being up to 144 weeks.

Descripción general del estudio

Estado

Inscripción por invitación

Condiciones

Intervención / Tratamiento

Tipo de estudio

Intervencionista

Inscripción (Estimado)

900

Fase

  • Fase 2

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

      • Leipzig, Alemania, 04347
        • Investigational Site Number : 2760001
      • Mainz, Alemania, 55128
        • Investigational Site Number : 2760005
      • Buenos Aires, Argentina, 1121
        • Investigational Site Number : 0320005
      • Buenos Aires, Argentina, 1414
        • Investigational Site Number : 0320004
      • Buenos Aires, Argentina, 1425
        • Investigational Site Number : 0320001
      • Buenos Aires, Argentina, 1122
        • Investigational Site Number : 0320012
      • Buenos Aires, Argentina, 1425
        • Investigational Site Number : 0320011
      • La Plata, Buenos Aires, Argentina, B1904CUL
        • Investigational Site Number : 0320003
      • Mendoza, Argentina, 5500
        • Investigational Site Number : 0320009
      • Mendoza, Argentina, 5500
        • Investigational Site Number : 0320015
      • Santa Fe, Argentina, 3000
        • Investigational Site Number : 0320010
    • Buenos Aires
      • Berazategui, Buenos Aires, Argentina, 1886
        • Investigational Site Number : 0320007
      • Lobos, Buenos Aires, Argentina, 7240
        • Investigational Site Number : 0320013
    • Santa Fe Province
      • Rosario, Santa Fe Province, Argentina, 2000
        • Investigational Site Number : 0320002
      • Rosario, Santa Fe Province, Argentina, 2000
        • Investigational Site Number : 0320006
      • Rosario, Santa Fe Province, Argentina, 2000
        • Investigational Site Number : 0320020
    • Tucumán Province
      • San Miguel de Tucumán, Tucumán Province, Argentina, 4000
        • Investigational Site Number : 0320008
      • Rio de Janeiro, Brasil, 22241-180
        • CCBR / IBPClin - Instituto Brasil de Pesquisa Clínica- Site Number : 0760006
      • São Paulo, Brasil, 05403-000
        • Incor - Instituto do Coracao- Site Number : 0760011
    • Estado de Bahia
      • Salvador, Estado de Bahia, Brasil, 40060-330
        • Associacao Proar- Site Number : 0760003
    • Goiás
      • Goiânia, Goiás, Brasil, 74605-020
        • Universidade Federal de Goias- Site Number : 0760007
    • Paraná
      • Curitiba, Paraná, Brasil, 80030-110
        • CETI - Centro de Estudos em Terapias Inovadoras- Site Number : 0760002
    • Pernambuco
      • Recife, Pernambuco, Brasil, 50070-550
        • Instituto de Medicina Integral Professor Fernando Figueira- Site Number : 0760009
    • Rio Grande do Sul
      • Porto Alegre, Rio Grande do Sul, Brasil, 90610-000
        • Hospital São Lucas da PUCRS - Porto Alegre - Avenida Ipiranga- Site Number : 0760001
    • Santa Catarina
      • Blumenau, Santa Catarina, Brasil, 89030-101
        • Hospital Dia do Pulmão- Site Number : 0760005
    • Ontario
      • Ajax, Ontario, Canadá, L1S 2J5
        • Investigational Site Number : 1240013
      • Hamilton, Ontario, Canadá, L8N 4A6
        • Investigational Site Number : 1240003
    • Quebec
      • Sherbrooke, Quebec, Canadá, J1H 5N4
        • Investigational Site Number : 1240004
      • Trois-Rivières, Quebec, Canadá, G8T 7A1
        • Investigational Site Number : 1240001
    • Biobio
      • Concepción, Biobio, Chile, 4070094
        • Investigational Site Number : 1520013
    • Maule Region
      • Talca, Maule Region, Chile, 3465584
        • Investigational Site Number : 1520001
    • Reg Metropolitana de Santiago
      • Recoleta, Reg Metropolitana de Santiago, Chile, 8420000
        • Investigational Site Number : 1520015
      • Santiago, Reg Metropolitana de Santiago, Chile, 7500587
        • Investigational Site Number : 1520006
      • Santiago, Reg Metropolitana de Santiago, Chile, 7500692
        • Investigational Site Number : 1520005
      • Santiago, Reg Metropolitana de Santiago, Chile, 7500698
        • Investigational Site Number : 1520004
      • Santiago, Reg Metropolitana de Santiago, Chile, 7750495
        • Investigational Site Number : 1520002
    • Valparaiso
      • Quillota, Valparaiso, Chile, 2260877
        • Investigational Site Number : 1520008
      • Viña del Mar, Valparaiso, Chile, 2531172
        • Investigational Site Number : 1520011
      • Viña del Mar, Valparaiso, Chile, 2540364
        • Investigational Site Number : 1520012
    • Seoul-teukbyeolsi
      • Seoul, Seoul-teukbyeolsi, Corea del Sur, 03722
        • Investigational Site Number : 4100001
      • Seoul, Seoul-teukbyeolsi, Corea del Sur, 03080
        • Investigational Site Number : 4100002
      • Seoul, Seoul-teukbyeolsi, Corea del Sur, 05030
        • Investigational Site Number : 4100004
      • Seoul, Seoul-teukbyeolsi, Corea del Sur, 05505
        • Investigational Site Number : 4100006
      • Seoul, Seoul-teukbyeolsi, Corea del Sur, 06351
        • Investigational Site Number : 4100005
      • Madrid, España, 28007
        • Investigational Site Number : 7240008
      • Madrid, España, 28010
        • Investigational Site Number : 7240011
    • Catalunya [Cataluña]
      • Barcelona, Catalunya [Cataluña], España, 08017
        • Investigational Site Number : 7240009
    • Arizona
      • Chandler, Arizona, Estados Unidos, 85224
        • Chandler Clinical Research Trials- Site Number : 8400075
      • Tucson, Arizona, Estados Unidos, 85712
        • Tucson Clinical Research Institute- Site Number : 8400085
    • Colorado
      • Aurora, Colorado, Estados Unidos, 80014
        • Allianz Research Institute - Aurora- Site Number : 8400026
      • Wheat Ridge, Colorado, Estados Unidos, 80033
        • Western States Clinical Research- Site Number : 8400014
    • Florida
      • Boynton Beach, Florida, Estados Unidos, 33435
        • Helix Biomedics- Site Number : 8400114
      • Cutler Bay, Florida, Estados Unidos, 33157
        • Beautiful Minds Clinical Research Center- Site Number : 8400049
      • Hialeah, Florida, Estados Unidos, 33010
        • Qway Research - Hialeah- Site Number : 8400015
      • Miami, Florida, Estados Unidos, 33184
        • High Quality Research- Site Number : 8400039
      • Miami, Florida, Estados Unidos, 33186
        • Innovations Biotech- Site Number : 8400040
      • Miami, Florida, Estados Unidos, 33186
        • New Access Medical Center- Site Number : 8400043
      • Miami, Florida, Estados Unidos, 33135
        • Clintex Research Group - Miami - Southwest 27th Avenue- Site Number : 8400048
      • Miami Lakes, Florida, Estados Unidos, 33014
        • Deluxe Health Center- Site Number : 8400045
      • Pembroke Pines, Florida, Estados Unidos, 33025
        • Tellabio International Research Services- Site Number : 8400083
      • Pembroke Pines, Florida, Estados Unidos, 33029
        • Alfa Medical Research LLC- Site Number : 8400146
      • Pensacola, Florida, Estados Unidos, 32503
        • Avanza Medical Research Center- Site Number : 8400135
      • Saint Cloud, Florida, Estados Unidos, 34769
        • Ilumina Medical Research- Site Number : 8400095
      • Sarasota, Florida, Estados Unidos, 34239
        • Windom Allergy, Asthma and Sinus Specialists- Site Number : 8400019
    • Georgia
      • Cordele, Georgia, Estados Unidos, 31015
        • Private Practice - Dr. David Kavtaradze- Site Number : 8400081
    • Massachusetts
      • Boston, Massachusetts, Estados Unidos, 02115
        • Brigham & Women's Hospital- Site Number : 8400034
    • Michigan
      • Ann Arbor, Michigan, Estados Unidos, 48109
        • University of Michigan Health System - Ann Arbor- Site Number : 8400004
    • Missouri
      • St Louis, Missouri, Estados Unidos, 63141
        • Midwest Clinical Research Center - St. Louis- Site Number : 8400006
    • North Carolina
      • Charlotte, North Carolina, Estados Unidos, 28287
        • Tryon Medical Partners - Charlotte - Piedmont Row Drive South- Site Number : 8400029
    • Ohio
      • Toledo, Ohio, Estados Unidos, 43617
        • Asthma & Allergy Center - Toledo- Site Number : 8400017
    • Oklahoma
      • Edmond, Oklahoma, Estados Unidos, 73034
        • OK Clinical Research- Site Number : 8400021
    • Pennsylvania
      • DuBois, Pennsylvania, Estados Unidos, 15801
        • Clinical Research Associates of Central Pennsylvania- Site Number : 8400116
      • Pittsburgh, Pennsylvania, Estados Unidos, 15241
        • Allergy & Clinical Immunology Associates Pittsburgh- Site Number : 8400007
    • Texas
      • Austin, Texas, Estados Unidos, 78759
        • Orion Clinical Research- Site Number : 8400001
      • Boerne, Texas, Estados Unidos, 78006
        • South Texas Medical Research Institute - TTS Research- Site Number : 8400010
      • Dallas, Texas, Estados Unidos, 75246
        • Baylor University Medical Center- Site Number : 8400002
      • El Paso, Texas, Estados Unidos, 79903
        • Western Sky Medical Research- Site Number : 8400023
      • McKinney, Texas, Estados Unidos, 75069
        • Metroplex Pulmonary and Sleep Center- Site Number : 8400022
      • Mosonmagyaróvár, Hungría, 9200
        • Investigational Site Number : 3480004
      • Calicut, India, 673008
        • Investigational Site Number : 3560007
      • Hyderabad, India, 500084
        • Investigational Site Number : 3560009
      • Kanpur, India, 208001
        • Investigational Site Number : 3560008
      • Nagpur, India, 441203
        • Investigational Site Number : 3560001
      • Pune, India, 411057
        • Investigational Site Number : 3560004
      • Ashkelon, Israel, 7830604
        • Investigational Site Number : 3760006
      • Haifa, Israel, 3104802
        • Investigational Site Number : 3760001
      • Haifa, Israel, 3436212
        • Investigational Site Number : 3760008
      • Jerusalem, Israel, 9103102
        • Investigational Site Number : 3760003
      • Jerusalem, Israel, 9112001
        • Investigational Site Number : 3760002
      • Petah Tikva, Israel, 4941492
        • Investigational Site Number : 3760010
      • Rehovot, Israel, 7610001
        • Investigational Site Number : 3760004
      • Tel Aviv, Israel, 6423906
        • Investigational Site Number : 3760007
    • Roma
      • Rome, Roma, Italia, 00168
        • Investigational Site Number : 3800010
      • Fukushima, Japón, 960-1295
        • Investigational Site Number : 3920008
      • Kyoto, Japón, 610-0113
        • Investigational Site Number : 3920006
      • Kyoto, Japón, 612-8555
        • Investigational Site Number : 3920009
      • Miyazaki, Japón, 889-1692
        • Investigational Site Number : 3920012
    • Kagawa-ken
      • Sakaidechō, Kagawa-ken, Japón, 762-8550
        • Investigational Site Number : 3920002
    • Tokyo
      • Chūō, Tokyo, Japón, 104-0031
        • Investigational Site Number : 3920011
    • Yamaguchi
      • Ube, Yamaguchi, Japón, 755-8505
        • Investigational Site Number : 3920005
      • Chihuahua City, México, 31000
        • Investigational Site Number : 4840002
      • Durango, México, 34000
        • Investigational Site Number : 4840003
      • Veracruz, México, 91900
        • Investigational Site Number : 4840008
    • Nuevo León
      • Monterrey, Nuevo León, México, 66465
        • Investigational Site Number : 4840004
    • Querétaro
      • San Juan del Río, Querétaro, México, 76800
        • Investigational Site Number : 4840005
    • Yucatán
      • Mérida, Yucatán, México, 97070
        • Investigational Site Number : 4840007
      • Chęciny, Polonia, 26-060
        • Investigational Site Number : 6160004
    • Greater Poland Voivodeship
      • Poznan, Greater Poland Voivodeship, Polonia, 60-693
        • Investigational Site Number : 6160001
      • Beijing, Porcelana, 100144
        • Investigational Site Number : 1560011
      • Changchun, Porcelana, 130021
        • Investigational Site Number : 1560010
      • Changsha, Porcelana, 410015
        • Investigational Site Number : 1560017
      • Chengde, Porcelana, 067020
        • Investigational Site Number : 1560021
      • Guangzhou, Porcelana, 510150
        • Investigational Site Number : 1560009
      • Guangzhou, Porcelana, 510000
        • Investigational Site Number : 1560053
      • Guangzhou, Porcelana, 510163
        • Investigational Site Number : 1560001
      • Guiyang, Porcelana, 550002
        • Investigational Site Number : 1560037
      • Hefei, Porcelana, 230032
        • Investigational Site Number : 1560006
      • Hohhot, Porcelana, 010050
        • Investigational Site Number : 1560014
      • Lanzhou, Porcelana, 730000
        • Investigational Site Number : 1560030
      • Nanchang, Porcelana, 330006
        • Investigational Site Number : 1560007
      • Pingxiang, Porcelana, 337055
        • Investigational Site Number : 1560002
      • Shanghai, Porcelana, 200433
        • Investigational Site Number : 1560013
      • Shenyang, Porcelana, 110004
        • Investigational Site Number : 1560015
      • Taiyuan, Porcelana, 030001
        • Investigational Site Number : 1560057
      • Tianjin, Porcelana, 300211
        • Investigational Site Number : 1560055
      • Wenzhou, Porcelana, 325027
        • Investigational Site Number : 1560005
      • Wuhan, Porcelana, 430030
        • Investigational Site Number : 1560003
      • Wuhan, Porcelana, 430030
        • Investigational Site Number : 1560022
      • Xuzhou, Porcelana, 221006
        • Investigational Site Number : 1560004
      • Yangzhou, Porcelana, 225000
        • Investigational Site Number : 1560016
      • Zhanjiang, Porcelana, 524004
        • Investigational Site Number : 1560012
      • Bradford, Reino Unido, BD9 6DA
        • Investigational Site Number : 8260008
      • Chertsey, Reino Unido
        • Investigational Site Number : 8260005
      • London, Reino Unido, W1G 8HU
        • Investigational Site Number : 8260011
    • Cambridgeshire
      • Cambridge, Cambridgeshire, Reino Unido, CB2 2QQ
        • Investigational Site Number : 8260001
    • Glasgow City
      • Glasgow, Glasgow City, Reino Unido, G12 0YN
        • Investigational Site Number : 8260004
      • Benoni, Sudáfrica, 1500
        • Investigational Site Number : 7100004
      • Benoni, Sudáfrica, 1500
        • Investigational Site Number : 7100005
      • Cape Town, Sudáfrica, 7530
        • Investigational Site Number : 7100003
      • Cape Town, Sudáfrica, 7700
        • Investigational Site Number : 7100002
      • Durban, Sudáfrica, 4001
        • Investigational Site Number : 7100001
      • Pretoria, Sudáfrica, 0157
        • Investigational Site Number : 7100006
      • Taipei, Taiwán, 110
        • Investigational Site Number : 1580003
      • Bursa, Turquía (Türkiye), 16059
        • Investigational Site Number : 7920006
      • Istanbul, Turquía (Türkiye), 34098
        • Investigational Site Number : 7920002
      • Istanbul, Turquía (Türkiye), 34854
        • Investigational Site Number : 7920003
      • Kayseri, Turquía (Türkiye), 38039
        • Investigational Site Number : 7920007
      • Kirikkale, Turquía (Türkiye), 71100
        • Investigational Site Number : 7920008
      • Mersin, Turquía (Türkiye), 33070
        • Investigational Site Number : 7920001
      • İzmit, Turquía (Türkiye), 41001
        • Investigational Site Number : 7920005

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Participants who completed the treatment period of Study DRI16762 or ACT18301, including the EOT visit, as per protocol

  • Participants with stable background therapy with moderate or high-dose ICS in combination with the following controller medications, as maintained during the respective parent study in which they have participated:

    • For Study DRI16762: At least 1 and no more than 2 additional controllers (eg, LABA, LAMA, LTRA, or methylxanthines), with or without oral prednisone
    • For Study ACT18301: LABA with or without LTRA
  • Participants who are able and willing to participate in the open-label extension study, and to comply with requested study visits and procedures

  • Contraception for male and female participants during the study intervention period and during 8 weeks following the last administration of study intervention. And:

For female participants:

  • incapable of becoming pregnant, or
  • not pregnant or breast feeding
  • no eggs donation or cryopreserving eggs

For male participants:

-- No sperm donation or cryopreserving sperm

- Capable of giving signed informed consent

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

  • Participant who developed a new medical condition or a change in status of an established medical condition or requires a new treatment or medication prior to enrollment that, per Investigator's medical judgement would adversely affect participation of the participant in this study or would require permanent lunsekimig discontinuation, or participants potentially at risk of noncompliance to study procedures
  • Participant who was diagnosed with a new pulmonary disease which may impair lung function
  • Current smoker or active vaping of any products and/or marijuana smoking
  • Prescription drug or substance abuse, including alcohol, considered significant by the Investigator
  • History of hypersensitivity or allergy to lunsekimig or to any of the excipients used in the presentation or in preparation for administration of lunsekimig, or other allergy that, in the opinion of the Investigator, contraindicates participation in the study
  • Participants who are receiving prohibited concomitant medications
  • Participants who, during their participation in the parent study, developed an AE or an SAE deemed related to lunsekimig, which in the opinion of the Investigator could indicate that continued treatment with lunsekimig may present an unreasonable risk for the participant

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: N / A
  • Modelo Intervencionista: Asignación de un solo grupo
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Lunsekimig

Participants will receive subcutaneous injection of lunsekimig according to established dosing interval

  • Pharmaceutical form: Solution for injection in vial or pre-filled syringe (PFS)
  • Route of administration: Subcutaneous injection
Otros nombres:
  • SAR443765

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Exposure-adjusted incidence rate of treatment-emergent adverse event (TEAE), including adverse events of special interest (AESI), and serious adverse event (SAE)
Periodo de tiempo: From study baseline to week 148

Exposure-adjusted incidence rate is defined as the number of patients with at least one specific treatment emergent adverse event in question per 100 patients taking the treatment for 1 year.

From study baseline to week 148

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Annualized rate of asthma exacerbation events
Periodo de tiempo: From study baseline to weeks 48, 96 and 144
From study baseline to weeks 48, 96 and 144
Change from parent study baseline in pre-bronchodilator (BD) forced expiratory volume in 1 second (FEV1)
Periodo de tiempo: From parent study baseline to weeks 48, 96 and 144
From parent study baseline to weeks 48, 96 and 144
Serum lunsekimig concentrations
Periodo de tiempo: From study baseline to week 144
From study baseline to week 144
Incidence and titer of anti-drug antibodies (ADA) against lunsekimig
Periodo de tiempo: From study baseline to week 144
From study baseline to week 144
Change from parent study baseline in Asthma Control Questionnaire5 (ACQ-5) score
Periodo de tiempo: From parent study baseline to weeks 48, 96 and 144

The ACQ-5 is a questionnaire that measures the adequacy of asthma control and any changes in asthma control that may occur spontaneously or as a result of treatment. The ACQ-5 has five questions on the asthma symptoms and patients are asked to recall how their asthma has been during the previous week and to respond on a 7-point scale for each question (0 = no impairment, 6 = maximum impairment). The ACQ-5 score is the mean of the 5 questions and, therefore, between 0 (totally controlled) and 6 (severely uncontrolled). A high score indicates low asthma control.

From parent study baseline to weeks 48, 96 and 144
Proportion of participants with ≥0.5-point reduction in each ACQ-5 score as compared to parent study baseline score
Periodo de tiempo: From parent study baseline to weeks 48, 96 and 144

Defined as ACQ-5 responder analysis

From parent study baseline to weeks 48, 96 and 144
Change from parent study baseline in Asthma Quality of Life Questionnaire Standardized Activites for 12 years and older (AQLQ[S] +12) domain and total scores
Periodo de tiempo: From parent study baseline to weeks 48, 96 and 144

The AQLQ(S) + 12 was designed as a self-administered patient reported outcome to measure the functional impairments that are most troublesome to adolescents and adults ≥12 years of age as a result of their asthma. The instrument is comprised of 32 items, each rated on a 7-point Likert scales from 1 to 7. Higher scores indicate better quality of life.

From parent study baseline to weeks 48, 96 and 144

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

30 de septiembre de 2024

Finalización primaria (Estimado)

20 de enero de 2031

Finalización del estudio (Estimado)

20 de enero de 2031

Fechas de registro del estudio

Enviado por primera vez

20 de septiembre de 2024

Primero enviado que cumplió con los criterios de control de calidad

20 de septiembre de 2024

Publicado por primera vez (Actual)

24 de septiembre de 2024

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

21 de septiembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

18 de septiembre de 2026

Última verificación

1 de septiembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • LTS17231
  • 2025-522896-27 (Identificador de registro: CTIS)
  • U1111-1303-3645 (Identificador de registro: ICTRP)
  • 2025 (Subvención/contrato del NIH de EE. UU.)

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Descripción del plan IPD

Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir